Psammoma Bodies in Lung Adenocarcinoma: Incidence and Association With ALK/ROS1/RET Fusions

被引：0
|
作者：
Li, Yuan
Shen, Xuxia
Wang, Rui
Hu, Haichuan
Chen, Haiquan
Mukhopadhyay, Sanjay
机构：
[1] Fudan Univ, Shanghai Canc Ctr, Shanghai 200433, Peoples R China
[2] Cleveland Clin, Cleveland, OH 44106 USA
来源：
MODERN PATHOLOGY | 2015年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
1937
引用
收藏
页码：483A / 483A
页数：1
相关论文
共 50 条
  • [31] Complementary Utility of Combined ALK/ROS1 FISH with Immunohistochemistry for ALK/ROS1 Rearrangement Testing in Lung Cancer
    Nambirajan, A.
    Singh, V.
    Rana, D.
    Malik, P.
    Mohan, A.
    Jain, D.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1160 - S1160
  • [32] Expression of C-terminal ALK, RET, or ROS1 in lung cancer cells with or without fusion
    Furugaki, Koh
    Mochizuki, Marie
    Kohno, Mirei
    Shu, Sei
    Harada, Naoki
    Yoshimura, Yasushi
    BMC CANCER, 2019, 19 (1)
  • [33] ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: A comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features
    Pan, Yunjian
    Zhang, Yang
    Li, Yuan
    Hu, Haichuan
    Wang, Lei
    Li, Hang
    Wang, Rui
    Ye, Ting
    Luo, Xiaoyang
    Zhang, Yiliang
    Li, Bin
    Cai, Deng
    Shen, Lei
    Sun, Yihua
    Chen, Haiquan
    LUNG CANCER, 2014, 84 (02) : 121 - 126
  • [34] Expression of C-terminal ALK, RET, or ROS1 in lung cancer cells with or without fusion
    Koh Furugaki
    Marie Mochizuki
    Mirei Kohno
    Sei Shu
    Naoki Harada
    Yasushi Yoshimura
    BMC Cancer, 19
  • [35] Development of the immuno-wall device for rapid detection of ALK and ROS1 fusions in lung cancer
    Yogo, N.
    Hase, T.
    Kasama, T.
    Hatta, T.
    Ozawa, N.
    Sato, M.
    Kaji, N.
    Tokeshi, M.
    Baba, Y.
    Hasegawa, Y.
    ANNALS OF ONCOLOGY, 2018, 29
  • [36] Overview of ALK and ROS1 Rearranged Lung Cancer
    Choi, Chang Min
    TUBERCULOSIS AND RESPIRATORY DISEASES, 2013, 75 (06) : 236 - 237
  • [37] ALK and ROS1 Overexpression is Very Rare in Colorectal Adenocarcinoma
    Houang, Michelle
    Toon, Christopher W.
    Clarkson, Adele
    Sioson, Loretta
    de Silva, Keshani
    Watson, Nicole
    Singh, Nisha R.
    Chou, Angela
    Gill, Anthony J.
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2015, 23 (02) : 134 - 138
  • [38] Emerging oncogenic fusions other than ALK, ROS1, RET, and NTRK in NSCLC and the role of fusions as resistance mechanisms t o targeted therapy
    Suda, Kenichi
    Mitsudomi, Tetsuya
    TRANSLATIONAL LUNG CANCER RESEARCH, 2020, 9 (06) : 2618 - 2628
  • [39] Early feasibility and development of multiplexed, single-reaction assays for ALK, ROS1 and RET novel ddPCR RNA fusions
    Mellert, Hestia
    Alexander, Kristin
    Jackson, Leisa
    Roda, Galen
    Cooper, Samantha
    Marr, Dianna
    Jones, Stephen J.
    Charrington, Nia
    Pestano, Gary
    CANCER RESEARCH, 2017, 77
  • [40] Clinical utility of liquid biopsy for molecular characterization and resistance detection in patients with advanced NSCLC and ALK, ROS1 or RET fusions
    Aldea, Mihaela
    Marinello, Arianna
    Tagliamento, Marco
    Dall'Olio, Filippo
    Vasseur, Damien
    Bayle, Arnaud
    Gazzah, Anas
    Grecea, Miruna
    Nicotra, Claudio
    Lacroix, Ludovic
    Ponce, Santiago
    Friboulet, Luc
    Barlesi, Fabrice
    Andre, Fabrice
    Planchard, David
    Rouleau, Etienne
    Italiano, Antoine
    Besse, Benjamin
    CANCER RESEARCH, 2023, 83 (07)
12345